9 completed, 1 terminated. 10 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 9, Terminated 1 |
Follow Elan Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis BG00002 (natalizumab), interferon beta-1a, glatiramer acetate - Relapsing Remitting Multiple Sclerosis | Phase 3 | Terminated | Biogen | 84 | 2010-03-01 | 2014-09-03 |
| Natalizumab Re-Initiation of Dosing BG00002 (natalizumab) - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Completed | Biogen | 404 | 2006-03-01 | 2017-03-21 |
| A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease natalizumab - Crohn's Disease | Phase 3 | Completed | Biogen | 462 | 2004-03-01 | 2016-06-16 |
| Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain Ziconotide - Pain | Phase 3 | Completed | Elan Pharmaceuticals | 300 | 2004-02-01 | 2015-12-14 |
| Prialt (Ziconotide) In Severe Chronic Pain Prialt (ziconotide) - Pain | Phase 3 | Completed | Elan Pharmaceuticals | 220 | 2002-08-01 | 2015-12-14 |
| Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity. tizanidine hydrochloride capsule - Multiple Sclerosis, Muscle Spasticity | Phase 3 | Completed | Elan Pharmaceuticals | 120 | 2002-06-01 | 2015-12-14 |
| Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease natalizumab - Crohn's Disease | Phase 3 | Completed | Biogen | 2002-03-01 | 2016-06-16 | |
| Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis Natalizumab, Placebo - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Completed | Biogen | 1200 | 2002-01-01 | 2009-06-18 |
| Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease natalizumab - Crohn's Disease | Phase 3 | Completed | Biogen | 905 | 2001-12-01 | 2016-06-16 |
| Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis Natalizumab, Placebo - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Completed | Biogen | 900 | 2001-11-01 | 2017-01-09 |
Multiple Sclerosis, Relapsing-Remitting (4) · Crohn Disease (3) · Multiple Sclerosis (3) · Pain (2) · Colitis (1) · Inflammatory Bowel Diseases (1) · Muscle Spasticity (1) · Spinal Cord Injuries (1) · Stroke (1)
Natalizumab (7) · ziconotide (2) · Glatiramer Acetate (1) · Interferon beta-1a (1) · tizanidine (1)
United States (9) · Canada (4) · France (3) · Belgium (2) · Czechia (2) · Germany (2) · Italy (2) · Australia (1) · Austria (1) · Finland (1) · Hungary (1) · Israel (1) · Latvia (1) · Netherlands (1) · Poland (1)
Michael Panzara, MD, MPH (2) · Chris Polman, MD (1) · Richard A Rudick, MD (1)
PMID 16267322, PMID 37173129, PMID 16510744, PMID 16510745, PMID 22521274, PMID 38469809